Cardiovascular complications of antineoplastic therapy in children

Cover Page

Abstract


The improvement of long-term survival in children with malignant tumors is noted in the last five decades. Serious late consequences of the applied therapy including early death, the second tumors, different organ dysfunctions (heart, gonads, liver, lungs) began to come to light with increase in number of cured and follow-up. The article discusses the emergence of cardiotoxicity in children treated with cytostatic and radiation therapy for malignant tumors. Particular attention is paid to the influence of anthracycline antibiotics on the state of the heart muscle. Anthracycline and similar medicines - doxorubicin, rubomycin, idarubicin, mitoxantrone - are an important component of most regimen of chemotherapy in children. Briefly describes the history of the application of this group of drugs in oncology and the study of their effects on heart function. The attention to the pathogenesis of anthracycline cardiotoxicity risk factors for its development, display options, how to identify and mitigate. We describe the clinical manifestations of early and late cardiotoxicity arising after the application of antitumor antibiotics anthracyclines. The article defines the role of chemotherapeutic agents other groups in the development and worsening cardiotoxicity. No less important role in the development of long-term effects of the heart and blood vessels plays radiotherapy. The paper paid attention to cardiovascular dysfunctions that arise in different periods of observation after irradiation of the mediastinum. Finally, recommendations for practitioners on screening, monitoring and treatment of identified diseases of the cardiovascular system in patients cured of childhood malignancies are presented.


Svetlana A Kulyova

Author for correspondence.
Kulevadoc@yandex.ru
N.N. Petrov Research Institute of Oncology
Russian Federation, Saint Petersburg, Russia

MD, PhD, Dr Med Sci, Associate Professor, Head. Department of Children`s Chemoterapy and Combined Modality Therapy

Tatiana Yu Semiglazova

Kulevadoc@yandex.ru
N.N. Petrov Research Institute of Oncology
Russian Federation, Saint Petersburg, Russia

MD, PhD, Dr Med Sci, Leading Scientist, Scientific Department of Innovative Methods of Therapy and Rehabilitation

Daria A Zvyagintseva

Kulevadoc@yandex.ru
N.N. Petrov Research Institute of Oncology
Russian Federation, Saint Petersburg, Russia

Postgraduate Student, Scientific Department of Innovative Methods of Therapy and Rehabilitation

Margarita B Belogurova

Kulevadoc@yandex.ru
St Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation, Saint Petersburg, Russia

MD, PhD, Dr Med Sci, Professor, Head, Department of Oncology with Radiology and Radiotherapy Course

Svetlana V Ivanova

Kulevadoc@yandex.ru
N.N. Petrov Research Institute of Oncology
Russian Federation, Saint Petersburg, Russia

Department of Children`s Chemoterapy and Combined Modality Therapy

Irina V Okisheva

Kulevadoc@yandex.ru
N.N. Petrov Research Institute of Oncology
Russian Federation, Saint Petersburg, Russia

Resident doctor, Scientific Department of Innovative Methods of Therapy and Rehabilitation

  • Adams MJ, Hardenbergh PH, Coustine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003;45:55-75. doi: 10.1016/S1040-8428(01)00227-X.
  • Goorin AM, Borow KM, Goldman A, et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer. 1981;47:2810-6. doi: 10.1002/1097-0142(19810615)47:12<2810::. AID-CNCR2820471210>3.0.CO;2-4.
  • Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol. 2001;19:1296-34. doi: 10.1200/jco.2001.19.7.1926.
  • Hancock SL, Tucker MA, Hoppe RT, et al. Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst. 1993;85:25-31. doi: 10.1093/jnci/85.1.25.
  • Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002. CA. 2002;52:23-47. doi: 10.3322/canjclin.52.1.23.
  • Kremer LC, Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191-6. doi: 10.1200/JCO.2001.19.1.191.
  • Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systemic review. Ann Oncol. 2002;13:819-29. doi: 10.1093/annonc/mdf167.
  • Krischer JP, Cuthberston DD, Epstein S, et al. Risk factors for early anthracycline clinical cardiotoxocity in children: the Pediatric Oncology Group Experience. Prog Pediart Cardiol. 1998;8:83-90. doi: 10.1016/S1058-9813(98)00005-8.
  • Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32: 302-14. doi: 10.1002/1097-0142(197308)32:2<302::. AID-CNCR2820320205>3.0.CO;2-2.
  • Lipshultz SE. Ventricular dysfunction clinical research infants, children, and adolescents. Prog Pediatr Cardiol. 2000;12:1-28. doi: 10.1016/S1058-9813(00)00076-X.
  • Lipshultz SE. Ventricular dysfunction clinical research n infants, children, and adolescents. Prog Pediatr Cardiol. 2000;12:1-28. doi: 10.1016/S1058-9813(00)00076-X.
  • Lipshultz SE, Rifai N, Dalton VM, et al. The effects of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-53. doi: 10.1056/NEJMoa035153.
  • Meadows AT. Risk factors for second malignant neoplasms: report from the Late Effects Study Group. Bull Cancer. 1988;75(1):125-30.
  • Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163-72. doi: 10.1200/JCO.2001.19.13.3163.
  • Moller TR, Garwitz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19:3173-81. doi: 10.1200/JCO.2001.19.13.3173.
  • Oberlin O. When quality of life is the major challenge. J Clin Oncol. 2002;20:3051-3. doi: 10.1200/JCO.2002.20.14.3051.
  • Pragga C, Berett G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827-34.
  • Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3502-8. doi: 10.1200/JCO.1998.16.11.3502.
  • Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. PediatrBlood Cancer. 2010;55:1145-52. doi: 10.1002/pbc.22664.
  • Sorenser K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61-8. doi: 10.1200/JCO.1997.15.1.61.
  • Sorenser K, Levitt G, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991-8. doi: 10.1002/cncr.11274.
  • Steinherz LJ, Steinherz PG, Tan Ch, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;226:1672-7. doi: 10.1001/jama.1991.03470120074036.
  • Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493-500. doi: 10.1200/JCO.2005.02.3879.
  • Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Inter Med. 1979;97:710-7. doi: 10.7326/0003-4819-91-5-710.
  • Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362-72. doi: 10.1200/JCO.1996.14.2.362.

Supplementary files

There are no supplementary files to display.

Views

Abstract - 125

PDF (Russian) - 115


Copyright (c) 2017 Kulyova S.A., Semiglazova T.Y., Zvyagintseva D.A., Belogurova M.B., Ivanova S.V., Okisheva I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.